The Board of Directors at its meeting held on May 19, 2026 has re-appointed M/s. BDO India LLP as Internal Auditor as per the disclosure annexed herewith.
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 5.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nephrocare Health Services reported audited standalone results for FY26 showing revenue of Rs. 6,297.43 million, up 15.8% from Rs. 5,435.97 million in FY25. However, the company swung to a net loss of Rs. 80.60 million for FY26 compared to a net profit of Rs. 342.36 million in FY25, primarily due to a significant increase in finance costs to Rs. 497.61 million (vs Rs. 142.99 million), which included a non-cash, non-recurring interest expense of Rs. 371.89 million on FVTPL financial liabilities. The board also approved investing up to Rs. 10 crore in its Nepal subsidiary, and providing collateral support of up to Rs. 70 crore each for its Singapore and Saudi Arabia subsidiaries. BDO India LLP was reappointed as Internal Auditor for FY27. The statutory auditor issued an unmodified opinion on the financial results.
The stock may face pressure due to the significant profit-to-loss turnaround, though the underlying revenue growth remains healthy. The large finance costs appear largely non-cash and related to IPO-related instruments, which investors may view as a one-time impact. The substantial collateral support for overseas subsidiaries increases exposure to international operations.